|
1
|
Klausner RD: The fabric of cancer cell
biology-Weaving together the strands. Cancer Cell. 1:3–10. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Navin N, Kendall J, Troge J, Andrews P,
Rodgers L, McIndoo J, Cook K, Stepansky A, Levy D, Esposito D, et
al: Tumour evolution inferred by single-cell sequencing. Nature.
472:90–94. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bissell MJ and Hines WC: Why don't we get
more cancer? A proposed role of the microenvironment in restraining
cancer progression. Nat Med. 17:320–329. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu W, Li L and Li W: Gene co-expression
analysis identifies common modules related to prognosis and drug
resistance in cancer cell lines. Int J Cancer. 135:2795–2803. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yadav VK and De S: An assessment of
computational methods for estimating purity and clonality using
genomic data derived from heterogeneous tumor tissue samples. Brief
Bioinform. 16:232–241. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yoshihara K, Shahmoradgoli M, Martinez E,
Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW,
Levine DA, et al: Inferring tumour purity and stromal and immune
cell admixture from expression data. Nat Commun. 4:26122013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Calon A, Espinet E, Palomo-Ponce S,
Tauriello DV, Iglesias M, Céspedes MV, Sevillano M, Nadal C, Jung
P, Zhang XH, et al: Dependency of colorectal cancer on a
TGF-β-driven program in stromal cells for metastasis initiation.
Cancer Cell. 22:571–584. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cheng Q, Chang JT, Gwin WR, Zhu J, Ambs S,
Geradts J and Lyerly HK: A signature of epithelial-mesenchymal
plasticity and stromal activation in primary tumor modulates late
recurrence in breast cancer independent of disease subtype. Breast
Cancer Res. 16:4072014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Teschendorff AE, Miremadi A, Pinder SE,
Ellis IO and Caldas C: An immune response gene expression module
identifies a good prognosis subtype in estrogen receptor negative
breast cancer. Genome Biol. 8:R1572007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Finak G, Bertos N, Pepin F, Sadekova S,
Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu
A, et al: Stromal gene expression predicts clinical outcome in
breast cancer. Nat Med. 14:518–527. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Isella C, Terrasi A, Bellomo SE, Petti C,
Galatola G, Muratore A, Mellano A, Senetta R, Cassenti A, Sonetto
C, et al: Stromal contribution to the colorectal cancer
transcriptome. Nat Genet. 47:312–319. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu Y, Grabsch H, Ivanova T, Tan IB, Murray
J, Ooi CH, Wright AI, West NP, Hutchins GG, Wu J, et al:
Comprehensive genomic meta-analysis identifies intra-tumoural
stroma as a predictor of survival in patients with gastric cancer.
Gut. 62:1100–1111. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bianchini G, Qi Y, Alvarez RH, Iwamoto T,
Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC,
Radvanyi L, et al: Molecular anatomy of breast cancer stroma and
its prognostic value in estrogen receptor-positive and -negative
cancers. J Clin Oncol. 28:4316–4323. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Calon A, Lonardo E, Berenguer-Llergo A,
Espinet E, Hernando-Momblona X, Iglesias M, Sevillano M,
Palomo-Ponce S, Tauriello DV, Byrom D, et al: Stromal gene
expression defines poor-prognosis subtypes in colorectal cancer.
Nat Genet. 47:320–329. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Meyer PN, Fu K, Greiner T, Smith L,
Delabie J, Gascoyne R, Ott G, Rosenwald A, Braziel R, Campo E, et
al: The stromal cell marker SPARC predicts for survival in patients
with diffuse large B-cell lymphoma treated with rituximab. Am J
Clin Pathol. 135:54–61. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Goossens N, Hoshida Y and Aguirre-Ghiso
JA: Origin and interpretation of cancer transcriptome profiling:
The essential role of the stroma in determining prognosis and drug
resistance. EMBO Mol Med. 7:1385–1387. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Quigley DA and Kristensen V: Predicting
prognosis and therapeutic response from interactions between
lymphocytes and tumor cells. Mol Oncol. 9:2054–2062. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rhodes DR and Chinnaiyan AM: Integrative
analysis of the cancer transcriptome. Nat Genet. 37 Suppl:S31–S37.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Uhlén M, Fagerberg L, Hallström BM,
Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C,
Sjöstedt E, Asplund A, et al: Proteomics. Tissue-based map of the
human proteome. Science. 347:12604192015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Team RC: R A language and environment for
statistical computing. Vienna Austria R Foundation for Statistical
Computing. http://www.R-project.orgFebruary 10–2015
|
|
21
|
Harrell FE Jr: rms: Regression Modeling
Strategies. R package version 4.1–3. http://CRAN.R-project.org/package=rms2014
|
|
22
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fehlker M, Huska MR, Jöns T,
Andrade-Navarro MA and Kemmner W: Concerted down-regulation of
immune-system related genes predicts metastasis in colorectal
carcinoma. BMC Cancer. 14:642014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Menendez D, Shatz M and Resnick MA:
Interactions between the tumor suppressor p53 and immune responses.
Curr Opin Oncol. 25:85–92. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bracci L, Schiavoni G, Sistigu A and
Belardelli F: Immune-based mechanisms of cytotoxic chemotherapy:
Implications for the design of novel and rationale-based combined
treatments against cancer. Cell Death Differ. 21:15–25. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tan LY, Martini C, Fridlender ZG, Bonder
CS, Brown MP and Ebert LM: Control of immune cell entry through the
tumour vasculature: A missing link in optimising melanoma
immunotherapy? Clin Trans Immunol. 6:e1342017. View Article : Google Scholar
|
|
27
|
Yoshihara K, Tsunoda T, Shigemizu D,
Fujiwara H, Hatae M, Fujiwara H, Masuzaki H, Katabuchi H, Kawakami
Y, Okamoto A, et al: High-risk ovarian cancer based on 126-gene
expression signature is uniquely characterized by downregulation of
antigen presentation pathway. Clin Cancer Res. 18:1374–1385. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hoshida Y, Villanueva A, Kobayashi M, Peix
J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, et
al: Gene expression in fixed tissues and outcome in hepatocellular
carcinoma. N Engl J Med. 359:1995–2004. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schreiber RD, Old LJ and Smyth MJ: Cancer
immunoediting: Integrating immunity's roles in cancer suppression
and promotion. Science. 331:1565–1570. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Linsley PS, Chaussabel D and Speake C: The
relationship of immune cell signatures to patient survival varies
within and between tumor types. PLoS One. 10:e01387262015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Donner A: Drug resistance: The stroma's
contribution. Nat Chem Biol. 8:7392012. View Article : Google Scholar
|
|
32
|
Russo A, Bazan V, Iacopetta B, Kerr D,
Soussi T and Gebbia N; TP53-CRC Collaborative Study Group, : The
TP53 colorectal cancer international collaborative study on the
prognostic and predictive significance of p53 mutation: Influence
of tumor site, type of mutation, and adjuvant treatment. J Clin
Oncol. 23:7518–7528. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Boyer J, McLean EG, Aroori S, Wilson P,
McCulla A, Carey PD, Longley DB and Johnston PG: Characterization
of p53 wild-type and null isogenic colorectal cancer cell lines
resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin
Cancer Res. 10:2158–2167. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cohen RL and Settleman J: From cancer
genomics to precision oncology-tissue's still an issue. Cell.
157:1509–1514. 2014. View Article : Google Scholar : PubMed/NCBI
|
